Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BUSPAR · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BUSPAR® 30 mg Tablet | DRUG | 1 x 30 mg, single-dose fed |
| Buspirone Hydrochloride 30 mg Tablet | DRUG | 1 x 30 mg, single-dose fed |
Inclusion Criteria: * Screening Demographics: All volunteers selected for this study will be healthy men or women 18 years of age or older at the time of dosing. The volunteer's body mass index (BMI) is less than or equal to 30. * Screening Procedures: Each volunteer will complete the screening pro...
BUSPAR is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with two completed trials evaluating buspirone hydrochloride 30mg tablets under fasting and non-fasting conditions. The drug is not approved and remains in clinical development.
BUSPAR is being developed by Teva Pharmaceutical Industries Limited, whose ticker is TEVA. The company is conducting Phase 1 clinical trials to evaluate the drug in healthy volunteers.
BUSPAR is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy volunteers. The drug is investigational and has not been approved.
BUSPAR has two completed Phase 1 trials: NCT00840398, a non-fasting study of buspirone hydrochloride 30mg tablets with 24 participants, and NCT00840606, a fasting study with 70 participants. Both trials were conducted in the United States with healthy volunteers aged 18 years and older.
BUSPAR is the brand name for buspirone hydrochloride, a small molecule. The clinical trials listed under BUSPAR evaluate buspirone hydrochloride 30mg tablets in healthy volunteers.